Read by QxMD icon Read


Abdel-Motaal M Fouda, Anees M Bazeed
In this report we address an unusual adverse effect of finasteride (Propecia 1 mg tablets) that was associated with painless hematuria and hematospermia in a 38-year-old healthy male during treatment of androgenic alopecia at a dose of 1 mg/day. It was found that the bleeding was linked to finasteride use as it occurred 2-3 days after use and stopped upon discontinuation of the drug. The patient was subjected to urological examination, laboratory investigations, and radiological imaging to identify the probable cause of bleeding...
October 31, 2017: Drug Safety—Case Reports
Wesley Ludwig, Michael Phillips
There are a significant number of men under 40 who experience erectile dysfunction (ED). In the past, the vast majority of cases were thought to be psychogenic in nature. Studies have identified organic etiologies in 15-72% of men with ED under 40. Organic etiologies include vascular, neurogenic, Peyronie's disease (PD), medication side effects and endocrinologic sources. Vascular causes are commonly due to focal arterial occlusive disease. Young men with multiple sclerosis, epilepsy and trauma in close proximity to the spinal cord are at increased risk of ED...
2014: Urologia Internationalis
Roger Collier
No abstract text is available yet for this article.
July 9, 2013: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
Michael S Irwig
OBJECTIVE: Finasteride, a commonly prescribed medication for male pattern hair loss, has recently been associated with persistent sexual side effects. In addition, depression has recently been added to the product labeling of Propecia (finasteride 1 mg). Finasteride reduces the levels of several neuroactive steroids linked to sexual function and depression. This study assesses depressive symptoms and suicidal thoughts in former users of finasteride who developed persistent sexual side effects despite the discontinuation of finasteride...
September 2012: Journal of Clinical Psychiatry
A W Rafi, R M Katz
Background. We examined the efficacy of a new regimen to treat AGA, with attention to male patients who are atopic. Objective. To assess the efficacy of a four-part regimen for the treatment of AGA in atopic and nonatopic patients. NuH Hair is a novel topical combination of finasteride, dutasteride, and minoxidil, which is blended in a hypoallergenic lotion. The other three components included Rogaine foam, Propecia, and ketoconazole shampoo. Methods. A prospective pilot study was conducted in 15 patients. All patients were assessed for the presence of atopy...
2011: ISRN Dermatology
Akio Sato, Akira Takeda
Before now, there has been no study of finasteride use exceeding 1 year in Japanese men with androgenetic alopecia (AGA) except the study subsequently conducted from the development phase. Since the launch of finasteride, no study in a larger population had been reported. Ethnic variation of the onset age, progressive nature and degree of hair loss of androgenetic alopecia are known. The therapeutic effect of oral finasteride (Propecia) was examined on androgenetic alopecia of Japanese men. The efficacy and safety of finasteride (1 mg tablet) was evaluated in Japanese men with AGA in the long term...
January 2012: Journal of Dermatology
Michael S Irwig, Swapna Kolukula
INTRODUCTION: Finasteride has been associated with reversible adverse sexual side effects in multiple randomized, controlled trials for the treatment of male pattern hair loss (MPHL). The Medicines and Healthcare Products Regulatory Agency of the United Kingdom and the Swedish Medical Products Agency have both updated their patient information leaflets to include a statement that "persistence of erectile dysfunction after discontinuation of treatment with Propecia has been reported in post-marketing use...
June 2011: Journal of Sexual Medicine
Rikk Lynn, Aleksandar Krunic
Finasteride at a dose of 1 mg (Propecia®) has been used for the treatment of androgenic alopecia in men. Though finasteride has been successfully used, there is ongoing controversy surrounding its use since the publication of the Prostate Cancer Prevention Trial (PCPT) which includes claims of increased risk for higher grade prostate cancers. This has produced confusion on consulting and treatment of patients interested in starting finasteride for androgenic alopecia. We felt there was a need to clarify further the results of PCPT for our readers and help understanding the real risk of prostate cancer development of patients on finasteride...
September 2010: Dermatologic Therapy
Yuval Ramot, Tali Czarnowicki, Abraham Zlotogorski
Finasteride (1 mg/day) is widely utilized by dermatologists for the treatment of androgenetic alopecia. Although enjoying a relatively good safety profile, several sex-related adverse effects have been reported with this drug. Here we report two cases of gynecomastia, one of them bilateral, caused by Propecia((R)) prescribed for the treatment of androgenetic alopecia. Although relatively rare, physicians should be aware of this side effect and inform their patients when prescribing this medication.
January 2009: International Journal of Trichology
Kimberly E Liu, Saleh Binsaleh, Kirk C Lo, Keith Jarvi
OBJECTIVE: To describe the results of two cases of azoospermia and severe oligospermia in men during and after cessation of finasteride 1 mg. DESIGN: Case report. SETTING: Tertiary-care hospital-based clinic for andrology/male infertility. PATIENT(S): Two patients with azoospermia and severe oligospermia using finasteride 1 mg for hair loss. INTERVENTION(S): Discontinuation of finasteride. MAIN OUTCOME MEASURE(S): Improvement in sperm concentration...
September 2008: Fertility and Sterility
Anthony V D'Amico, Claus G Roehrborn
BACKGROUND: Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA). When men taking this treatment undergo screening for prostate cancer, a compensatory adjustment of the PSA concentration (to multiply the value by two) is recommended. Whether this recommendation should apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown. We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss...
January 2007: Lancet Oncology
Hitoshi Fukuzumi, Takanori Ikeda, Hirohisa Narita, Takatoshi Takubo, Takuma Matsuda, Tadaaki Taniguchi
No abstract text is available yet for this article.
June 2006: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
F Gianfrate
This conference focused on 'lifestyle' drugs, the kind of medicines treating conditions not considered as diseases, such as erectile dysfunction, male baldness, stress, etc, to improve quality of life and well-being. The lifestyle area is the fastest growing area in pharmaceuticals, driven by drugs such as Viagra (sildenafil; Pfizer Inc), Propecia (finasteride; Merck & Co Inc), Xenical (orlistat; F Hoffmann-La Roche Ltd) and others. The aging population in developed countries has a new perception of health, which is an improvement of wellness...
November 1999: IDrugs: the Investigational Drugs Journal
K D Kaufman, R P Dawber
In men who are genetically predisposed to develop androgenetic alopecia (AGA; male pattern hair loss), endogenous androgens alter scalp hair follicles, resulting in production of vellus-like, miniaturised hair, rather than cosmetically significant terminal hair. This change leads to a progressive decline in visible scalp hair density, readily perceived by the patient as thinning and, eventually, baldness. Dihydrotestosterone (DHT), a metabolite of testosterone produced by the enzyme 5alpha-reductase, has been implicated as the specific androgen in the pathogenesis of AGA...
April 1999: Expert Opinion on Investigational Drugs
Ronni Wolf, Jennifer L Parish, Lawrence Charles Parish
No abstract text is available yet for this article.
March 2005: Skinmed
Patrick C Walsh
No abstract text is available yet for this article.
January 2005: Journal of Urology
J-L Schmutz, A Barbaud, P Trechot
No abstract text is available yet for this article.
June 2004: Annales de Dermatologie et de Vénéréologie
William Rosner
No abstract text is available yet for this article.
July 2004: Journal of Clinical Endocrinology and Metabolism
Marvin J Rapaport
BACKGROUND: Finasteride (Propecia) was approved by the FDA in 1998 for treating men with androgenetic alopecia. The published clinical trials demonstrated statistical differences between drug and placebo. Rarely do new drugs undergo further non-drug-company-sponsored studies of efficacy. Concerns about clinical studies and marketing of drugs prompted this evaluation of a large group of patients taking this medication. OBJECTIVE: Finasteride usage offered an opportunity not only to understand the acceptance of a cosmetically oriented medication, but also to evaluate subjective comments and compliance after a long period of time...
May 2004: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"